From Our Partners
Wednesday, July 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

CUBRC, EpiVax Awarded DTRA Contract for Burkholderia Vaccine Antigen Design

by Global Biodefense Staff
January 3, 2017
Gram Negative Burkholderia pseudomallei

Gram-negative Burkholderia pseudomallei bacteria, which was grown on a medium of sheep’s blood agar for 72 hours. Background image credit: Dr. Todd Parker/CDC

Gram Negative Burkholderia pseudomalleiCUBRC’s Biological and Medical Sciences team, in collaboration with EpiVax, Inc., has received a four-year grant worth $1.87 million from the Defense Threat Reduction Agency (DTRA).

CUBRC, EpiVax and scientists at the University of Florida will be investigating immune cells from patients that were previously infected with Burkholderia pseudomallei to understand how this bacterium evades the human immune system and use that information to engineer an effective vaccine.

“A successful outcome of this basic research program will provide answers to some very difficult questions about how this pathogen evades the host immune system and position our team to identify multiple vaccine candidates for advanced development,” noted Katie Edwards, Ph.D., CUBRC’s Co-Principal Investigator and program lead.

EpiVax contributes expertise in immuno-informatics tools to speed the pace of vaccine development and provide rapid clues about the likelihood of success in human trials.

“EpiVax has worked hard to be at the forefront of vaccine antigen selection using our proprietary computational vaccinology tools. These tools make it possible to develop safer, more efficient vaccines and accelerate the development of new vaccines for national biodefense,” stated Annie De Groot, MD, EpiVax’s CEO and Co-Principal Investigator for the program.

CUBRC announced the award on Dec. 19, 2016.

From Our Partners
Tags: AwardsBurkholderiaDefense Threat Reduction Agency

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC